WHAT WE DO
Biohope Ltd. is a biomedical company focused in the research and development of novel solutions, to personalize and optimize the clinical management of chronic inflammation in patients under treatment with immunosuppressive and/or immunomodulatory therapies.
To develop innovative, honest, simple, and viable science to help improve human lives.
Biohope strives to be a leader in the generation of scientifically and socioeconomically sustainable innovative solutions in the field of immunologically based diseases.
Creative innovation – Quality work – Commitment to the project and to society Scientific, economic, and social transparency – Free expression of talent
CORE GOALS
To facilitate medical doctors to personalize and optimize the medical treatment in their patients with organ transplantation and rheumatoid arthritis.
To market INMUNOBIOGRAM as a simple & highly scalable technology easy to use.
Start worldwide sales from 2020
Create a highly motivating and creative company environment.
WE ARE ON PLAN
Biohope is a fast-growing company that has achieved significant goals in less than three years of existence, and we keep on moving!
INMUNOBIOGRAM R+D Plan
RENAL TRANSPLANTATION. Biohope has successfully finished a National Study (BH-Pilot). We work with 8 top-class Transplant Units of 4 EU countries and MGH (Harvard School of Medicine) in an International Multicenter clinical Study
RHEUMATOID ARTHRITIS. Biohope is initiating a national study to adapt the Inmunobiogram® technology to this new indication.
INMUNOBIOGRAM Patents
We have applied for several EU patents and PCT for the technology under our bioassay INMUNOBIOGRAM, and we expect the project will deliver further industrial property.
ORGANIZATIONS
The National Transplant Organization of Spain, the most renowned transplant organization in Europe, supported this project to be scaled up to European scope. We also have been offered support to the project from 5 Public Administration entities.
INMUNOBIOGRAM-Regulatory and Product Development
Functional prototype and user interface ongoing. Quality Assurance System (ISO 13485) in progress to obtain CE Mark. FDA approval follows 510 K pathway.